Nuritas, a biotechnology company, has recently raised $45 million in a Series B funding round. Nuritas is at the forefront of revolutionizing the development of plant-based bioactive peptides. This round was led by Cleveland Avenue, LLC, which includes Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund, Vertex Holdings, Veronorte, and CJ. Cultivian Sandbox Ventures and VisVires New Protein, who led previous rounds, also participated.
Since its founding in 2014, Nuritas has grown its Advisory Board. They currently have onboard Indra Nooyi, former CEO of Pepsico and board member at Amazon, Joerg Ohle of Bayer’s Global Consumer Health division, and Bruce German, professor and chemist of food science and technology at the University of California, Davis, and the director o...
